- Home
- LXEO vs LRMR Comparison
LXEO vs LRMR Comparison
Compare LXEO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXEO | LRMR |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.9M | 455.8M |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LXEO | LRMR |
|---|---|---|
| Price | $5.86 | $3.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $18.44 | $16.50 |
| AVG Volume (30 Days) | 613.5K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $654,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.43 | $1.73 |
| 52 Week High | $10.99 | $6.42 |
Technical Indicators
Market Signals| Indicator | LXEO | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 37.18 |
| Support Level | $5.54 | $3.87 |
| Resistance Level | $6.08 | $4.29 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 23.85 | 11.22 |
Price Performance
Historical ComparisonAbout LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.